Literature DB >> 28670687

Improved estimation of the cumulative incidence of rare outcomes.

David Benkeser1, Marco Carone2, Peter B Gilbert3.   

Abstract

Studying the incidence of rare events is both scientifically important and statistically challenging. When few events are observed, standard survival analysis estimators behave erratically, particularly if covariate adjustment is necessary. In these settings, it is possible to improve upon existing estimators by considering estimation in a bounded statistical model. This bounded model incorporates existing scientific knowledge about the incidence of an event in the population. Estimators that are guaranteed to agree with existing scientific knowledge on event incidence may exhibit superior behavior relative to estimators that ignore this knowledge. Focusing on the setting of competing risks, we propose estimators of cumulative incidence that are guaranteed to respect a bounded model and show that when few events are observed, the proposed estimators offer improvements over existing estimators in bias and variance. We illustrate the proposed estimators using data from a recent preventive HIV vaccine efficacy trial.
Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  competing risks; rare events; survival analysis; targeted minimum loss-based estimation

Mesh:

Substances:

Year:  2017        PMID: 28670687      PMCID: PMC5735003          DOI: 10.1002/sim.7337

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  13 in total

1.  Super learner.

Authors:  Mark J van der Laan; Eric C Polley; Alan E Hubbard
Journal:  Stat Appl Genet Mol Biol       Date:  2007-09-16

2.  Targeted minimum loss based estimation of causal effects of multiple time point interventions.

Authors:  Mark J van der Laan; Susan Gruber
Journal:  Int J Biostat       Date:  2012       Impact factor: 0.968

3.  Targeted maximum likelihood estimation of effect modification parameters in survival analysis.

Authors:  Ori M Stitelman; C William Wester; Victor De Gruttola; Mark J van der Laan
Journal:  Int J Biostat       Date:  2011-03-30       Impact factor: 0.968

4.  A targeted maximum likelihood estimator of a causal effect on a bounded continuous outcome.

Authors:  Susan Gruber; Mark J van der Laan
Journal:  Int J Biostat       Date:  2010-08-01       Impact factor: 0.968

5.  Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma.

Authors:  Elizabeth B Andrews; Alicia Gilsenan; Kirk Midkiff; David Harris
Journal:  Ann Epidemiol       Date:  2016-08-31       Impact factor: 3.797

6.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

7.  Estimating Effects with Rare Outcomes and High Dimensional Covariates: Knowledge is Power.

Authors:  Laura Balzer; Jennifer Ahern; Sandro Galea; Mark van der Laan
Journal:  Epidemiol Methods       Date:  2016-05-24

8.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

9.  Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.

Authors:  P B Gilbert; S G Self; M A Ashby
Journal:  Biometrics       Date:  1998-09       Impact factor: 2.571

10.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Authors:  Morgane Rolland; Paul T Edlefsen; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Tomer Hertz; Allan C deCamp; Chris Carrico; Sergey Menis; Craig A Magaret; Hasan Ahmed; Michal Juraska; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; Jason S McLellan; Ivelin Georgiev; Peter D Kwong; Jonathan M Carlson; Nelson L Michael; William R Schief; Peter B Gilbert; James I Mullins; Jerome H Kim
Journal:  Nature       Date:  2012-09-10       Impact factor: 49.962

View more
  5 in total

Review 1.  Heterogeneity in design and analysis of ICU delirium randomized trials: a systematic review.

Authors:  Elizabeth Colantuoni; Mounica Koneru; Narjes Akhlaghi; Ximin Li; Mohamed D Hashem; Victor D Dinglas; Karin J Neufeld; Michael O Harhay; Dale M Needham
Journal:  Trials       Date:  2021-05-20       Impact factor: 2.279

2.  Improving Precision and Power in Randomized Trials for COVID-19 Treatments Using Covariate Adjustment, for Binary, Ordinal, and Time-to-Event Outcomes.

Authors:  David Benkeser; Iván Díaz; Alex Luedtke; Jodi Segal; Daniel Scharfstein; Michael Rosenblum
Journal:  medRxiv       Date:  2020-06-11

3.  Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes.

Authors:  David Benkeser; Iván Díaz; Alex Luedtke; Jodi Segal; Daniel Scharfstein; Michael Rosenblum
Journal:  Biometrics       Date:  2020-10-11       Impact factor: 1.701

4.  Optimising precision and power by machine learning in randomised trials with ordinal and time-to-event outcomes with an application to COVID-19.

Authors:  Nicholas Williams; Michael Rosenblum; Iván Díaz
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2022-09-23       Impact factor: 2.175

5.  Assessing trends in vaccine efficacy by pathogen genetic distance.

Authors:  David Benkeser; Michal Juraska; Peter B Gilbert
Journal:  J Soc Fr Statistique (2009)       Date:  2020-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.